login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
KAIROS PHARMA LTD (KAPA) Stock News
USA
- NYSEARCA:KAPA -
US48301N1046
-
Common Stock
1.245
USD
+0.03 (+2.05%)
Last: 10/7/2025, 2:56:28 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
KAPA Latest News, Press Relases and Analysis
All
Press Releases
18 days ago - By: Chartmill
- Mentions:
CNFR
BHF
QMCO
SONN
...
Top movers in Friday's session
19 days ago - By: Chartmill
- Mentions:
GV
INTC
WHLR
ADAP
...
Here are the top movers in Thursday's session.
7 hours ago - By: Kairos Pharma, Ltd
Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025
18 days ago - By: Benzinga
- Mentions:
CCM
APVO
AQST
SONN
...
12 Health Care Stocks Moving In Friday's Intraday Session
18 days ago - By: Benzinga
- Mentions:
VTEX
LASE
CEVA
ATMV
...
Why FedEx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
19 days ago - By: Chartmill
- Mentions:
PBM
GV
EDUC
INTC
...
Traders are paying attention to the gapping stocks in Thursday's session.
19 days ago - By: Kairos Pharma, Ltd
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year
a month ago - By: Kairos Pharma, Ltd
Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
a month ago - By: Kairos Pharma, Ltd
Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025
a month ago - By: Kairos Pharma, Ltd
Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
3 months ago - By: Kairos Pharma, Ltd
Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
3 months ago - By: Kairos Pharma, Ltd
Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer
Please enable JavaScript to continue using this application.